

1 AN ACT concerning criminal law.

2 **Be it enacted by the People of the State of Illinois,**  
3 **represented in the General Assembly:**

4 Section 5. The Illinois Controlled Substances Act is  
5 amended by changing Sections 102 and 204 as follows:

6 (720 ILCS 570/102) (from Ch. 56 1/2, par. 1102)

7 Sec. 102. Definitions. As used in this Act, unless the  
8 context otherwise requires:

9 (a) "Addict" means any person who habitually uses any drug,  
10 chemical, substance or dangerous drug other than alcohol so as  
11 to endanger the public morals, health, safety or welfare or who  
12 is so far addicted to the use of a dangerous drug or controlled  
13 substance other than alcohol as to have lost the power of self  
14 control with reference to his or her addiction.

15 (b) "Administer" means the direct application of a  
16 controlled substance, whether by injection, inhalation,  
17 ingestion, or any other means, to the body of a patient,  
18 research subject, or animal (as defined by the Humane  
19 Euthanasia in Animal Shelters Act) by:

20 (1) a practitioner (or, in his or her presence, by his  
21 or her authorized agent),

22 (2) the patient or research subject pursuant to an  
23 order, or

1 (3) a euthanasia technician as defined by the Humane  
2 Euthanasia in Animal Shelters Act.

3 (c) "Agent" means an authorized person who acts on behalf  
4 of or at the direction of a manufacturer, distributor,  
5 dispenser, prescriber, or practitioner. It does not include a  
6 common or contract carrier, public warehouseman or employee of  
7 the carrier or warehouseman.

8 (c-1) "Anabolic Steroids" means any drug or hormonal  
9 substance, chemically and pharmacologically related to  
10 testosterone (other than estrogens, progestins,  
11 corticosteroids, and dehydroepiandrosterone), and includes:

- 12 (i) 3[beta],17-dihydroxy-5a-androstane,  
13 (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane,  
14 (iii) 5[alpha]-androstane-3,17-dione,  
15 (iv) 1-androstenediol (3[beta],  
16 17[beta]-dihydroxy-5[alpha]-androst-1-ene),  
17 (v) 1-androstenediol (3[alpha],  
18 17[beta]-dihydroxy-5[alpha]-androst-1-ene),  
19 (vi) 4-androstenediol  
20 (3[beta],17[beta]-dihydroxy-androst-4-ene),  
21 (vii) 5-androstenediol  
22 (3[beta],17[beta]-dihydroxy-androst-5-ene),  
23 (viii) 1-androstenedione  
24 ([5alpha]-androst-1-en-3,17-dione),  
25 (ix) 4-androstenedione  
26 (androst-4-en-3,17-dione),

- 1 (x) 5-androstenedione  
2 (androst-5-en-3,17-dione),  
3 (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]-  
4 hydroxyandrost-4-en-3-one),  
5 (xii) boldenone (17[beta]-hydroxyandrost-  
6 1,4,-diene-3-one),  
7 (xiii) boldione (androsta-1,4-  
8 diene-3,17-dione),  
9 (xiv) calusterone (7[beta],17[alpha]-dimethyl-17  
10 [beta]-hydroxyandrost-4-en-3-one),  
11 (xv) clostebol (4-chloro-17[beta]-  
12 hydroxyandrost-4-en-3-one),  
13 (xvi) dehydrochloromethyltestosterone (4-chloro-  
14 17[beta]-hydroxy-17[alpha]-methyl-  
15 androst-1,4-dien-3-one),  
16 (xvii) desoxymethyltestosterone  
17 (17[alpha]-methyl-5[alpha]  
18 -androst-2-en-17[beta]-ol) (a.k.a., madol),  
19 (xviii) [delta]1-dihydrotestosterone (a.k.a.  
20 '1-testosterone') (17[beta]-hydroxy-  
21 5[alpha]-androst-1-en-3-one),  
22 (xix) 4-dihydrotestosterone (17[beta]-hydroxy-  
23 androstan-3-one),  
24 (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl-  
25 5[alpha]-androstan-3-one),  
26 (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-

1 hydroxyestr-4-ene),  
2 (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl-  
3 1[beta],17[beta]-dihydroxyandrost-4-en-3-one),  
4 (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha],  
5 17[beta]-dihydroxyandrost-1,4-dien-3-one),  
6 (xxiv) furazabol (17[alpha]-methyl-17[beta]-  
7 hydroxyandrostano[2,3-c]-furazan),  
8 (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one~~→~~  
9 (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy-  
10 androst-4-en-3-one),  
11 (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]-  
12 dihydroxy-estr-4-en-3-one),  
13 (xxviii) mestanolone (17[alpha]-methyl-17[beta]-  
14 hydroxy-5-androstan-3-one),  
15 (xxix) mesterolone (1-methyl-17[beta]-hydroxy-  
16 [5a]-androstan-3-one),  
17 (xxx) methandienone (17[alpha]-methyl-17[beta]-  
18 hydroxyandrost-1,4-dien-3-one),  
19 (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]-  
20 dihydroxyandrost-5-ene),  
21 (xxxii) methenolone (1-methyl-17[beta]-hydroxy-  
22 5[alpha]-androst-1-en-3-one),  
23 (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]-  
24 dihydroxy-5a-androstane~~→~~,  
25 (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy  
26 -5a-androstane~~→~~,

- 1 (xxxv) 17[alpha]-methyl-3[beta],17[beta]-  
2 dihydroxyandrost-4-ene),
- 3 (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-  
4 methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one),
- 5 (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-  
6 hydroxyestra-4,9(10)-dien-3-one),
- 7 (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-  
8 hydroxyestra-4,9-11-trien-3-one),
- 9 (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-  
10 hydroxyandrost-4-en-3-one),
- 11 (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]-  
12 hydroxyestr-4-en-3-one),
- 13 (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone  
14 (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]-  
15 androst-1-en-3-one) (a.k.a. '17-[alpha]-methyl-  
16 1-testosterone'),
- 17 (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one),
- 18 (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]-  
19 dihydroxyestr-4-ene),
- 20 (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]-  
21 dihydroxyestr-4-ene),
- 22 (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]-  
23 dihydroxyestr-5-ene),
- 24 (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]-  
25 dihydroxyestr-5-ene),
- 26 (xlvii) 19-nor-4,9(10)-androstadienedione

1 (estra-4,9(10)-diene-3,17-dione),  
2 (xlvi) 19-nor-4-androstenedione (estr-4-  
3 en-3,17-dione),  
4 (xlix) 19-nor-5-androstenedione (estr-5-  
5 en-3,17-dione),  
6 (l) norbolethone (13[beta], 17a-diethyl-17[beta]-  
7 hydroxygon-4-en-3-one),  
8 (li) norclostebol (4-chloro-17[beta]-  
9 hydroxyestr-4-en-3-one),  
10 (lii) norethandrolone (17[alpha]-ethyl-17[beta]-  
11 hydroxyestr-4-en-3-one),  
12 (liii) normethandrolone (17[alpha]-methyl-17[beta]-  
13 hydroxyestr-4-en-3-one),  
14 (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-  
15 2-oxa-5[alpha]-androstan-3-one),  
16 (lv) oxymesterone (17[alpha]-methyl-4,17[beta]-  
17 dihydroxyandrost-4-en-3-one),  
18 (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene-  
19 17[beta]-hydroxy-(5[alpha]-androstan-3-one),  
20 (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy-  
21 (5[alpha]-androst-2-eno[3,2-c]-pyrazole),  
22 (lviii) stenbolone (17[beta]-hydroxy-2-methyl-  
23 (5[alpha]-androst-1-en-3-one),  
24 (lix) testolactone (13-hydroxy-3-oxo-13,17-  
25 secoandrosta-1,4-dien-17-oic  
26 acid lactone),

- 1 (lx) testosterone (17[beta]-hydroxyandrost-  
2 4-en-3-one),  
3 (lxi) tetrahydrogestrinone (13[beta], 17[alpha]-  
4 diethyl-17[beta]-hydroxygon-  
5 4,9,11-trien-3-one),  
6 (lxii) trenbolone (17[beta]-hydroxyestr-4,9,  
7 11-trien-3-one).

8 Any person who is otherwise lawfully in possession of an  
9 anabolic steroid, or who otherwise lawfully manufactures,  
10 distributes, dispenses, delivers, or possesses with intent to  
11 deliver an anabolic steroid, which anabolic steroid is  
12 expressly intended for and lawfully allowed to be administered  
13 through implants to livestock or other nonhuman species, and  
14 which is approved by the Secretary of Health and Human Services  
15 for such administration, and which the person intends to  
16 administer or have administered through such implants, shall  
17 not be considered to be in unauthorized possession or to  
18 unlawfully manufacture, distribute, dispense, deliver, or  
19 possess with intent to deliver such anabolic steroid for  
20 purposes of this Act.

21 (d) "Administration" means the Drug Enforcement  
22 Administration, United States Department of Justice, or its  
23 successor agency.

24 (d-5) "Clinical Director, Prescription Monitoring Program"  
25 means a Department of Human Services administrative employee  
26 licensed to either prescribe or dispense controlled substances

1 who shall run the clinical aspects of the Department of Human  
2 Services Prescription Monitoring Program and its Prescription  
3 Information Library.

4 (d-10) "Compounding" means the preparation and mixing of  
5 components, excluding flavorings, (1) as the result of a  
6 prescriber's prescription drug order or initiative based on the  
7 prescriber-patient-pharmacist relationship in the course of  
8 professional practice or (2) for the purpose of, or incident  
9 to, research, teaching, or chemical analysis and not for sale  
10 or dispensing. "Compounding" includes the preparation of drugs  
11 or devices in anticipation of receiving prescription drug  
12 orders based on routine, regularly observed dispensing  
13 patterns. Commercially available products may be compounded  
14 for dispensing to individual patients only if both of the  
15 following conditions are met: (i) the commercial product is not  
16 reasonably available from normal distribution channels in a  
17 timely manner to meet the patient's needs and (ii) the  
18 prescribing practitioner has requested that the drug be  
19 compounded.

20 (e) "Control" means to add a drug or other substance, or  
21 immediate precursor, to a Schedule whether by transfer from  
22 another Schedule or otherwise.

23 (f) "Controlled Substance" means (i) a drug, substance,  
24 immediate precursor, or synthetic drug in the Schedules of  
25 Article II of this Act or (ii) a drug or other substance, or  
26 immediate precursor, designated as a controlled substance by

1 the Department through administrative rule. The term does not  
2 include distilled spirits, wine, malt beverages, or tobacco, as  
3 those terms are defined or used in the Liquor Control Act of  
4 1934 and the Tobacco Products Tax Act of 1995.

5 (f-5) "Controlled substance analog" means a substance:

6 (1) the chemical structure of which is substantially  
7 similar to the chemical structure of a controlled substance  
8 in Schedule I or II;

9 (2) which has a stimulant, depressant, or  
10 hallucinogenic effect on the central nervous system that is  
11 substantially similar to or greater than the stimulant,  
12 depressant, or hallucinogenic effect on the central  
13 nervous system of a controlled substance in Schedule I or  
14 II; or

15 (3) with respect to a particular person, which such  
16 person represents or intends to have a stimulant,  
17 depressant, or hallucinogenic effect on the central  
18 nervous system that is substantially similar to or greater  
19 than the stimulant, depressant, or hallucinogenic effect  
20 on the central nervous system of a controlled substance in  
21 Schedule I or II.

22 (g) "Counterfeit substance" means a controlled substance,  
23 which, or the container or labeling of which, without  
24 authorization bears the trademark, trade name, or other  
25 identifying mark, imprint, number or device, or any likeness  
26 thereof, of a manufacturer, distributor, or dispenser other

1 than the person who in fact manufactured, distributed, or  
2 dispensed the substance.

3 (h) "Deliver" or "delivery" means the actual, constructive  
4 or attempted transfer of possession of a controlled substance,  
5 with or without consideration, whether or not there is an  
6 agency relationship.

7 (i) "Department" means the Illinois Department of Human  
8 Services (as successor to the Department of Alcoholism and  
9 Substance Abuse) or its successor agency.

10 (j) (Blank).

11 (k) "Department of Corrections" means the Department of  
12 Corrections of the State of Illinois or its successor agency.

13 (l) "Department of Financial and Professional Regulation"  
14 means the Department of Financial and Professional Regulation  
15 of the State of Illinois or its successor agency.

16 (m) "Depressant" means any drug that (i) causes an overall  
17 depression of central nervous system functions, (ii) causes  
18 impaired consciousness and awareness, and (iii) can be  
19 habit-forming or lead to a substance abuse problem, including  
20 but not limited to alcohol, cannabis and its active principles  
21 and their analogs, benzodiazepines and their analogs,  
22 barbiturates and their analogs, opioids (natural and  
23 synthetic) and their analogs, and chloral hydrate and similar  
24 sedative hypnotics.

25 (n) (Blank).

26 (o) "Director" means the Director of the Illinois State

1 Police or his or her designated agents.

2 (p) "Dispense" means to deliver a controlled substance to  
3 an ultimate user or research subject by or pursuant to the  
4 lawful order of a prescriber, including the prescribing,  
5 administering, packaging, labeling, or compounding necessary  
6 to prepare the substance for that delivery.

7 (q) "Dispenser" means a practitioner who dispenses.

8 (r) "Distribute" means to deliver, other than by  
9 administering or dispensing, a controlled substance.

10 (s) "Distributor" means a person who distributes.

11 (t) "Drug" means (1) substances recognized as drugs in the  
12 official United States Pharmacopoeia, Official Homeopathic  
13 Pharmacopoeia of the United States, or official National  
14 Formulary, or any supplement to any of them; (2) substances  
15 intended for use in diagnosis, cure, mitigation, treatment, or  
16 prevention of disease in man or animals; (3) substances (other  
17 than food) intended to affect the structure of any function of  
18 the body of man or animals and (4) substances intended for use  
19 as a component of any article specified in clause (1), (2), or  
20 (3) of this subsection. It does not include devices or their  
21 components, parts, or accessories.

22 (t-3) "Electronic health record" or "EHR" means an  
23 electronic record of health-related information on an  
24 individual that is created, gathered, managed, and consulted by  
25 authorized health care clinicians and staff.

26 (t-4) "Emergency medical services personnel" has the

1 meaning ascribed to it in the Emergency Medical Services (EMS)  
2 Systems Act.

3 (t-5) "Euthanasia agency" means an entity certified by the  
4 Department of Financial and Professional Regulation for the  
5 purpose of animal euthanasia that holds an animal control  
6 facility license or animal shelter license under the Animal  
7 Welfare Act. A euthanasia agency is authorized to purchase,  
8 store, possess, and utilize Schedule II nonnarcotic and  
9 Schedule III nonnarcotic drugs for the sole purpose of animal  
10 euthanasia.

11 (t-10) "Euthanasia drugs" means Schedule II or Schedule III  
12 substances (nonnarcotic controlled substances) that are used  
13 by a euthanasia agency for the purpose of animal euthanasia.

14 (u) "Good faith" means the prescribing or dispensing of a  
15 controlled substance by a practitioner in the regular course of  
16 professional treatment to or for any person who is under his or  
17 her treatment for a pathology or condition other than that  
18 individual's physical or psychological dependence upon or  
19 addiction to a controlled substance, except as provided herein:  
20 and application of the term to a pharmacist shall mean the  
21 dispensing of a controlled substance pursuant to the  
22 prescriber's order which in the professional judgment of the  
23 pharmacist is lawful. The pharmacist shall be guided by  
24 accepted professional standards including, but not limited to  
25 the following, in making the judgment:

26 (1) lack of consistency of prescriber-patient

1 relationship,

2 (2) frequency of prescriptions for same drug by one  
3 prescriber for large numbers of patients,

4 (3) quantities beyond those normally prescribed,

5 (4) unusual dosages (recognizing that there may be  
6 clinical circumstances where more or less than the usual  
7 dose may be used legitimately),

8 (5) unusual geographic distances between patient,  
9 pharmacist and prescriber,

10 (6) consistent prescribing of habit-forming drugs.

11 (u-0.5) "Hallucinogen" means a drug that causes markedly  
12 altered sensory perception leading to hallucinations of any  
13 type.

14 (u-1) "Home infusion services" means services provided by a  
15 pharmacy in compounding solutions for direct administration to  
16 a patient in a private residence, long-term care facility, or  
17 hospice setting by means of parenteral, intravenous,  
18 intramuscular, subcutaneous, or intraspinal infusion.

19 (u-5) "Illinois State Police" means the State Police of the  
20 State of Illinois, or its successor agency.

21 (v) "Immediate precursor" means a substance:

22 (1) which the Department has found to be and by rule  
23 designated as being a principal compound used, or produced  
24 primarily for use, in the manufacture of a controlled  
25 substance;

26 (2) which is an immediate chemical intermediary used or

1           likely to be used in the manufacture of such controlled  
2           substance; and

3           (3) the control of which is necessary to prevent,  
4           curtail or limit the manufacture of such controlled  
5           substance.

6           (w) "Instructional activities" means the acts of teaching,  
7           educating or instructing by practitioners using controlled  
8           substances within educational facilities approved by the State  
9           Board of Education or its successor agency.

10          (x) "Local authorities" means a duly organized State,  
11          County or Municipal peace unit or police force.

12          (y) "Look-alike substance" means a substance, other than a  
13          controlled substance which (1) by overall dosage unit  
14          appearance, including shape, color, size, markings or lack  
15          thereof, taste, consistency, or any other identifying physical  
16          characteristic of the substance, would lead a reasonable person  
17          to believe that the substance is a controlled substance, or (2)  
18          is expressly or impliedly represented to be a controlled  
19          substance or is distributed under circumstances which would  
20          lead a reasonable person to believe that the substance is a  
21          controlled substance. For the purpose of determining whether  
22          the representations made or the circumstances of the  
23          distribution would lead a reasonable person to believe the  
24          substance to be a controlled substance under this clause (2) of  
25          subsection (y), the court or other authority may consider the  
26          following factors in addition to any other factor that may be

1 relevant:

2 (a) statements made by the owner or person in control  
3 of the substance concerning its nature, use or effect;

4 (b) statements made to the buyer or recipient that the  
5 substance may be resold for profit;

6 (c) whether the substance is packaged in a manner  
7 normally used for the illegal distribution of controlled  
8 substances;

9 (d) whether the distribution or attempted distribution  
10 included an exchange of or demand for money or other  
11 property as consideration, and whether the amount of the  
12 consideration was substantially greater than the  
13 reasonable retail market value of the substance.

14 Clause (1) of this subsection (y) shall not apply to a  
15 noncontrolled substance in its finished dosage form that was  
16 initially introduced into commerce prior to the initial  
17 introduction into commerce of a controlled substance in its  
18 finished dosage form which it may substantially resemble.

19 Nothing in this subsection (y) prohibits the dispensing or  
20 distributing of noncontrolled substances by persons authorized  
21 to dispense and distribute controlled substances under this  
22 Act, provided that such action would be deemed to be carried  
23 out in good faith under subsection (u) if the substances  
24 involved were controlled substances.

25 Nothing in this subsection (y) or in this Act prohibits the  
26 manufacture, preparation, propagation, compounding,

1 processing, packaging, advertising or distribution of a drug or  
2 drugs by any person registered pursuant to Section 510 of the  
3 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).

4 (y-1) "Mail-order pharmacy" means a pharmacy that is  
5 located in a state of the United States that delivers,  
6 dispenses or distributes, through the United States Postal  
7 Service or other common carrier, to Illinois residents, any  
8 substance which requires a prescription.

9 (z) "Manufacture" means the production, preparation,  
10 propagation, compounding, conversion or processing of a  
11 controlled substance other than methamphetamine, either  
12 directly or indirectly, by extraction from substances of  
13 natural origin, or independently by means of chemical  
14 synthesis, or by a combination of extraction and chemical  
15 synthesis, and includes any packaging or repackaging of the  
16 substance or labeling of its container, except that this term  
17 does not include:

18 (1) by an ultimate user, the preparation or compounding  
19 of a controlled substance for his or her own use; or

20 (2) by a practitioner, or his or her authorized agent  
21 under his or her supervision, the preparation,  
22 compounding, packaging, or labeling of a controlled  
23 substance:

24 (a) as an incident to his or her administering or  
25 dispensing of a controlled substance in the course of  
26 his or her professional practice; or

1 (b) as an incident to lawful research, teaching or  
2 chemical analysis and not for sale.

3 (z-1) (Blank).

4 (z-5) "Medication shopping" means the conduct prohibited  
5 under subsection (a) of Section 314.5 of this Act.

6 (z-10) "Mid-level practitioner" means (i) a physician  
7 assistant who has been delegated authority to prescribe through  
8 a written delegation of authority by a physician licensed to  
9 practice medicine in all of its branches, in accordance with  
10 Section 7.5 of the Physician Assistant Practice Act of 1987,  
11 (ii) an advanced practice registered nurse who has been  
12 delegated authority to prescribe through a written delegation  
13 of authority by a physician licensed to practice medicine in  
14 all of its branches or by a podiatric physician, in accordance  
15 with Section 65-40 of the Nurse Practice Act, (iii) an advanced  
16 practice registered nurse certified as a nurse practitioner,  
17 nurse midwife, or clinical nurse specialist who has been  
18 granted authority to prescribe by a hospital affiliate in  
19 accordance with Section 65-45 of the Nurse Practice Act, (iv)  
20 an animal euthanasia agency, or (v) a prescribing psychologist.

21 (aa) "Narcotic drug" means any of the following, whether  
22 produced directly or indirectly by extraction from substances  
23 of vegetable origin, or independently by means of chemical  
24 synthesis, or by a combination of extraction and chemical  
25 synthesis:

26 (1) opium, opiates, derivatives of opium and opiates,

1 including their isomers, esters, ethers, salts, and salts  
2 of isomers, esters, and ethers, whenever the existence of  
3 such isomers, esters, ethers, and salts is possible within  
4 the specific chemical designation; however the term  
5 "narcotic drug" does not include the isoquinoline  
6 alkaloids of opium;

7 (2) (blank);

8 (3) opium poppy and poppy straw;

9 (4) coca leaves, except coca leaves and extracts of  
10 coca leaves from which substantially all of the cocaine and  
11 ecgonine, and their isomers, derivatives and salts, have  
12 been removed;

13 (5) cocaine, its salts, optical and geometric isomers,  
14 and salts of isomers;

15 (6) ecgonine, its derivatives, their salts, isomers,  
16 and salts of isomers;

17 (7) any compound, mixture, or preparation which  
18 contains any quantity of any of the substances referred to  
19 in subparagraphs (1) through (6).

20 (bb) "Nurse" means a registered nurse licensed under the  
21 Nurse Practice Act.

22 (cc) (Blank).

23 (dd) "Opiate" means any substance having an addiction  
24 forming or addiction sustaining liability similar to morphine  
25 or being capable of conversion into a drug having addiction  
26 forming or addiction sustaining liability.

1 (ee) "Opium poppy" means the plant of the species *Papaver*  
2 *somniferum* L., except its seeds.

3 (ee-5) "Oral dosage" means a tablet, capsule, elixir, or  
4 solution or other liquid form of medication intended for  
5 administration by mouth, but the term does not include a form  
6 of medication intended for buccal, sublingual, or transmucosal  
7 administration.

8 (ff) "Parole and Pardon Board" means the Parole and Pardon  
9 Board of the State of Illinois or its successor agency.

10 (gg) "Person" means any individual, corporation,  
11 mail-order pharmacy, government or governmental subdivision or  
12 agency, business trust, estate, trust, partnership or  
13 association, or any other entity.

14 (hh) "Pharmacist" means any person who holds a license or  
15 certificate of registration as a registered pharmacist, a local  
16 registered pharmacist or a registered assistant pharmacist  
17 under the Pharmacy Practice Act.

18 (ii) "Pharmacy" means any store, ship or other place in  
19 which pharmacy is authorized to be practiced under the Pharmacy  
20 Practice Act.

21 (ii-5) "Pharmacy shopping" means the conduct prohibited  
22 under subsection (b) of Section 314.5 of this Act.

23 (ii-10) "Physician" (except when the context otherwise  
24 requires) means a person licensed to practice medicine in all  
25 of its branches.

26 (jj) "Poppy straw" means all parts, except the seeds, of

1 the opium poppy, after mowing.

2 (kk) "Practitioner" means a physician licensed to practice  
3 medicine in all its branches, dentist, optometrist, podiatric  
4 physician, veterinarian, scientific investigator, pharmacist,  
5 physician assistant, advanced practice registered nurse,  
6 licensed practical nurse, registered nurse, emergency medical  
7 services personnel, hospital, laboratory, or pharmacy, or  
8 other person licensed, registered, or otherwise lawfully  
9 permitted by the United States or this State to distribute,  
10 dispense, conduct research with respect to, administer or use  
11 in teaching or chemical analysis, a controlled substance in the  
12 course of professional practice or research.

13 (ll) "Pre-printed prescription" means a written  
14 prescription upon which the designated drug has been indicated  
15 prior to the time of issuance; the term does not mean a written  
16 prescription that is individually generated by machine or  
17 computer in the prescriber's office.

18 (mm) "Prescriber" means a physician licensed to practice  
19 medicine in all its branches, dentist, optometrist,  
20 prescribing psychologist licensed under Section 4.2 of the  
21 Clinical Psychologist Licensing Act with prescriptive  
22 authority delegated under Section 4.3 of the Clinical  
23 Psychologist Licensing Act, podiatric physician, or  
24 veterinarian who issues a prescription, a physician assistant  
25 who issues a prescription for a controlled substance in  
26 accordance with Section 303.05, a written delegation, and a

1 written collaborative agreement required under Section 7.5 of  
2 the Physician Assistant Practice Act of 1987, an advanced  
3 practice registered nurse with prescriptive authority  
4 delegated under Section 65-40 of the Nurse Practice Act and in  
5 accordance with Section 303.05, a written delegation, and a  
6 written collaborative agreement under Section 65-35 of the  
7 Nurse Practice Act, an advanced practice registered nurse  
8 certified as a nurse practitioner, nurse midwife, or clinical  
9 nurse specialist who has been granted authority to prescribe by  
10 a hospital affiliate in accordance with Section 65-45 of the  
11 Nurse Practice Act and in accordance with Section 303.05, or an  
12 advanced practice registered nurse certified as a nurse  
13 practitioner, nurse midwife, or clinical nurse specialist who  
14 has full practice authority pursuant to Section 65-43 of the  
15 Nurse Practice Act.

16 (nn) "Prescription" means a written, facsimile, or oral  
17 order, or an electronic order that complies with applicable  
18 federal requirements, of a physician licensed to practice  
19 medicine in all its branches, dentist, podiatric physician or  
20 veterinarian for any controlled substance, of an optometrist in  
21 accordance with Section 15.1 of the Illinois Optometric  
22 Practice Act of 1987, of a prescribing psychologist licensed  
23 under Section 4.2 of the Clinical Psychologist Licensing Act  
24 with prescriptive authority delegated under Section 4.3 of the  
25 Clinical Psychologist Licensing Act, of a physician assistant  
26 for a controlled substance in accordance with Section 303.05, a

1 written delegation, and a written collaborative agreement  
2 required under Section 7.5 of the Physician Assistant Practice  
3 Act of 1987, of an advanced practice registered nurse with  
4 prescriptive authority delegated under Section 65-40 of the  
5 Nurse Practice Act who issues a prescription for a controlled  
6 substance in accordance with Section 303.05, a written  
7 delegation, and a written collaborative agreement under  
8 Section 65-35 of the Nurse Practice Act, of an advanced  
9 practice registered nurse certified as a nurse practitioner,  
10 nurse midwife, or clinical nurse specialist who has been  
11 granted authority to prescribe by a hospital affiliate in  
12 accordance with Section 65-45 of the Nurse Practice Act and in  
13 accordance with Section 303.05 when required by law, or of an  
14 advanced practice registered nurse certified as a nurse  
15 practitioner, nurse midwife, or clinical nurse specialist who  
16 has full practice authority pursuant to Section 65-43 of the  
17 Nurse Practice Act.

18 (nn-5) "Prescription Information Library" (PIL) means an  
19 electronic library that contains reported controlled substance  
20 data.

21 (nn-10) "Prescription Monitoring Program" (PMP) means the  
22 entity that collects, tracks, and stores reported data on  
23 controlled substances and select drugs pursuant to Section 316.

24 (oo) "Production" or "produce" means manufacture,  
25 planting, cultivating, growing, or harvesting of a controlled  
26 substance other than methamphetamine.

1 (pp) "Registrant" means every person who is required to  
2 register under Section 302 of this Act.

3 (qq) "Registry number" means the number assigned to each  
4 person authorized to handle controlled substances under the  
5 laws of the United States and of this State.

6 (qq-5) "Secretary" means, as the context requires, either  
7 the Secretary of the Department or the Secretary of the  
8 Department of Financial and Professional Regulation, and the  
9 Secretary's designated agents.

10 (rr) "State" includes the State of Illinois and any state,  
11 district, commonwealth, territory, insular possession thereof,  
12 and any area subject to the legal authority of the United  
13 States of America.

14 (rr-5) "Stimulant" means any drug that (i) causes an  
15 overall excitation of central nervous system functions, (ii)  
16 causes impaired consciousness and awareness, and (iii) can be  
17 habit-forming or lead to a substance abuse problem, including  
18 but not limited to amphetamines and their analogs,  
19 methylphenidate and its analogs, cocaine, and phencyclidine  
20 and its analogs.

21 (rr-10) "Synthetic drug" includes, but is not limited to,  
22 any synthetic cannabinoids or piperazines or any synthetic  
23 cathinones as provided for in Schedule I.

24 (ss) "Ultimate user" means a person who lawfully possesses  
25 a controlled substance for his or her own use or for the use of  
26 a member of his or her household or for administering to an

1 animal owned by him or her or by a member of his or her  
2 household.

3 (Source: P.A. 99-78, eff. 7-20-15; 99-173, eff. 7-29-15;  
4 99-371, eff. 1-1-16; 99-480, eff. 9-9-15; 99-642, eff. 7-28-16;  
5 100-280, eff. 1-1-18; 100-453, eff. 8-25-17; 100-513, eff.  
6 1-1-18; revised 10-6-17.)

7 (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204)

8 Sec. 204. (a) The controlled substances listed in this  
9 Section are included in Schedule I.

10 (b) Unless specifically excepted or unless listed in  
11 another schedule, any of the following opiates, including their  
12 isomers, esters, ethers, salts, and salts of isomers, esters,  
13 and ethers, whenever the existence of such isomers, esters,  
14 ethers and salts is possible within the specific chemical  
15 designation:

16 (1) Acetylmethadol;

17 (1.1) Acetyl-alpha-methylfentanyl

18 (N-[1-(1-methyl-2-phenethyl)-

19 4-piperidinyl]-N-phenylacetamide);

20 (2) Allylprodine;

21 (3) Alphacetylmethadol, except

22 levo-alphacetylmethadol (also known as levo-alpha-  
23 acetylmethadol, levomethadyl acetate, or LAAM);

24 (4) Alphameprodine;

25 (5) Alphamethadol;

- 1 (6) Alpha-methylfentanyl
- 2 (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
- 3 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
- 4 propanilido) piperidine;
- 5 (6.1) Alpha-methylthiofentanyl
- 6 (N-[1-methyl-2-(2-thienyl) ethyl-
- 7 4-piperidinyl]-N-phenylpropanamide);
- 8 (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
- 9 (7.1) PEPAP
- 10 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
- 11 (8) Benzethidine;
- 12 (9) Betacetylmethadol;
- 13 (9.1) Beta-hydroxyfentanyl
- 14 (N-[1-(2-hydroxy-2-phenethyl)-
- 15 4-piperidinyl]-N-phenylpropanamide);
- 16 (10) Betameprodine;
- 17 (11) Betamethadol;
- 18 (12) Betaprodine;
- 19 (13) Clonitazene;
- 20 (14) Dextromoramide;
- 21 (15) Diampromide;
- 22 (16) Diethylthiambutene;
- 23 (17) Difenoazin;
- 24 (18) Dimenoxadol;
- 25 (19) Dimepheptanol;
- 26 (20) Dimethylthiambutene;

- 1 (21) Dioxaphetylbutyrate;
- 2 (22) Dipipanone;
- 3 (23) Ethylmethylthiambutene;
- 4 (24) Etonitazene;
- 5 (25) Etoxeridine;
- 6 (26) Furethidine;
- 7 (27) Hydroxypethidine;
- 8 (28) Ketobemidone;
- 9 (29) Levomoramide;
- 10 (30) Levophenacymorphan;
- 11 (31) 3-Methylfentanyl
- 12 (N-[3-methyl-1-(2-phenylethyl)-
- 13 4-piperidyl]-N-phenylpropanamide);
- 14 (31.1) 3-Methylthiofentanyl
- 15 (N-[(3-methyl-1-(2-thienyl)ethyl-
- 16 4-piperidinyl]-N-phenylpropanamide);
- 17 (32) Morpheridine;
- 18 (33) Noracymethadol;
- 19 (34) Norlevorphanol;
- 20 (35) Normethadone;
- 21 (36) Norpipanone;
- 22 (36.1) Para-fluorofentanyl
- 23 (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
- 24 4-piperidinyl]propanamide);
- 25 (37) Phenadoxone;
- 26 (38) Phenampromide;

- 1 (39) Phenomorphan;
- 2 (40) Phenoperidine;
- 3 (41) Piritramide;
- 4 (42) Proheptazine;
- 5 (43) Properidine;
- 6 (44) Propiram;
- 7 (45) Racemoramide;
- 8 (45.1) Thiofentanyl
- 9 (N-phenyl-N-[1-(2-thienyl)ethyl-
- 10 4-piperidinyl]-propanamide);
- 11 (46) Tilidine;
- 12 (47) Trimeperidine;
- 13 (48) Beta-hydroxy-3-methylfentanyl (other name:
- 14 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
- 15 N-phenylpropanamide);
- 16 (49) Furanyl fentanyl (FU-F);
- 17 (50) Butyryl fentanyl;
- 18 (51) Valeryl fentanyl;
- 19 (52) Acetyl fentanyl;
- 20 (53) Beta-hydroxy-thiofentanyl;
- 21 (54) 3,4-dichloro-N-[2-
- 22 (dimethylamino)cyclohexyl]-N-
- 23 methylbenzamide (U-47700);
- 24 (55) 4-chloro-N-[1-[2-
- 25 (4-nitrophenyl)ethyl]-2-piperidinylidene]-
- 26 benzenesulfonamide (W-18);

1 (56) 4-chloro-N-[1-(2-phenylethyl)  
2 -2-piperidinylidene]-benzenesulfonamide (W-15);

3 (57) acrylfentanyl (acryloylfentanyl).

4 (c) Unless specifically excepted or unless listed in  
5 another schedule, any of the following opium derivatives, its  
6 salts, isomers and salts of isomers, whenever the existence of  
7 such salts, isomers and salts of isomers is possible within the  
8 specific chemical designation:

- 9 (1) Acetorphine;
- 10 (2) Acetyldihydrocodeine;
- 11 (3) Benzylmorphine;
- 12 (4) Codeine methylbromide;
- 13 (5) Codeine-N-Oxide;
- 14 (6) Cyprenorphine;
- 15 (7) Desomorphine;
- 16 (8) Diacetyldihydromorphine (Dihydroheroin);
- 17 (9) Dihydromorphine;
- 18 (10) Drotebanol;
- 19 (11) Etorphine (except hydrochloride salt);
- 20 (12) Heroin;
- 21 (13) Hydromorphanol;
- 22 (14) Methyldesorphine;
- 23 (15) Methyldihydromorphine;
- 24 (16) Morphine methylbromide;
- 25 (17) Morphine methylsulfonate;
- 26 (18) Morphine-N-Oxide;

- 1 (19) Myrophine;
- 2 (20) Nicocodeine;
- 3 (21) Nicomorphine;
- 4 (22) Normorphine;
- 5 (23) Pholcodine;
- 6 (24) Thebacon.

7 (d) Unless specifically excepted or unless listed in  
8 another schedule, any material, compound, mixture, or  
9 preparation which contains any quantity of the following  
10 hallucinogenic substances, or which contains any of its salts,  
11 isomers and salts of isomers, whenever the existence of such  
12 salts, isomers, and salts of isomers is possible within the  
13 specific chemical designation (for the purposes of this  
14 paragraph only, the term "isomer" includes the optical,  
15 position and geometric isomers):

- 16 (1) 3,4-methylenedioxyamphetamine  
17 (alpha-methyl, 3,4-methylenedioxyphenethylamine,  
18 methylenedioxyamphetamine, MDA);
  - 19 (1.1) Alpha-ethyltryptamine  
20 (some trade or other names: etryptamine;  
21 MONASE; alpha-ethyl-1H-indole-3-ethanamine;  
22 3-(2-aminobutyl)indole; a-ET; and AET);
- 23 (2) 3,4-methylenedioxymethamphetamine (MDMA);
  - 24 (2.1) 3,4-methylenedioxy-N-ethylamphetamine  
25 (also known as: N-ethyl-alpha-methyl-  
26 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,

- 1 and MDEA);
- 2 (2.2) N-Benzylpiperazine (BZP);
- 3 (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);
- 4 (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
- 5 (4) 3,4,5-trimethoxyamphetamine (TMA);
- 6 (5) (Blank);
- 7 (6) Diethyltryptamine (DET);
- 8 (7) Dimethyltryptamine (DMT);
- 9 (7.1) 5-Methoxy-diallyltryptamine;
- 10 (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
- 11 (9) Ibogaine (some trade and other names:
- 12 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
- 13 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
- 14 indole; Tabernanthe iboga);
- 15 (10) Lysergic acid diethylamide;
- 16 (10.1) Salvinorin A;
- 17 (10.5) Salvia divinorum (meaning all parts of the plant
- 18 presently classified botanically as Salvia divinorum,
- 19 whether growing or not, the seeds thereof, any extract from
- 20 any part of that plant, and every compound, manufacture,
- 21 salts, isomers, and salts of isomers whenever the existence
- 22 of such salts, isomers, and salts of isomers is possible
- 23 within the specific chemical designation, derivative,
- 24 mixture, or preparation of that plant, its seeds or
- 25 extracts);
- 26 (11) 3,4,5-trimethoxyphenethylamine (Mescaline);

1 (12) Peyote (meaning all parts of the plant presently  
2 classified botanically as *Lophophora williamsii* Lemaire,  
3 whether growing or not, the seeds thereof, any extract from  
4 any part of that plant, and every compound, manufacture,  
5 salts, derivative, mixture, or preparation of that plant,  
6 its seeds or extracts);

7 (13) N-ethyl-3-piperidyl benzilate (JB 318);

8 (14) N-methyl-3-piperidyl benzilate;

9 (14.1) N-hydroxy-3,4-methylenedioxyamphetamine  
10 (also known as N-hydroxy-alpha-methyl-  
11 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);

12 (15) Parahexyl; some trade or other names:  
13 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-  
14 dibenzo (b,d) pyran; Synhexyl;

15 (16) Psilocybin;

16 (17) Psilocyn;

17 (18) Alpha-methyltryptamine (AMT);

18 (19) 2,5-dimethoxyamphetamine  
19 (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);

20 (20) 4-bromo-2,5-dimethoxyamphetamine  
21 (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;  
22 4-bromo-2,5-DMA);

23 (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.  
24 Some trade or other names: 2-(4-bromo-  
25 2,5-dimethoxyphenyl)-1-aminoethane;  
26 alpha-desmethyl DOB, 2CB, Nexus;

- 1 (21) 4-methoxyamphetamine  
2 (4-methoxy-alpha-methylphenethylamine;  
3 paramethoxyamphetamine; PMA);  
4 (22) (Blank);  
5 (23) Ethylamine analog of phencyclidine.  
6 Some trade or other names:  
7 N-ethyl-1-phenylcyclohexylamine,  
8 (1-phenylcyclohexyl) ethylamine,  
9 N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;  
10 (24) Pyrrolidine analog of phencyclidine. Some trade  
11 or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,  
12 PHP;  
13 (25) 5-methoxy-3,4-methylenedioxy-amphetamine;  
14 (26) 2,5-dimethoxy-4-ethylamphetamine  
15 (another name: DOET);  
16 (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine  
17 (another name: TCPy);  
18 (28) (Blank);  
19 (29) Thiophene analog of phencyclidine (some trade  
20 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;  
21 2-thienyl analog of phencyclidine; TPCP; TCP);  
22 (29.1) Benzothiophene analog of phencyclidine. Some  
23 trade or other names: BTCP or benocyclidine;  
24 (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);  
25 (30) Bufotenine (some trade or other names:  
26 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;

1 3-(2-dimethylaminoethyl)-5-indolol;  
2 5-hydroxy-N,N-dimethyltryptamine;  
3 N,N-dimethylserotonin; mappine);  
4 (31) (Blank);  
5 (32) (Blank);  
6 (33) (Blank);  
7 (34) (Blank);  
8 (34.5) (Blank);  
9 (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-  
10 (2-methyloctan-2-yl)-6a,7,  
11 10,10a-tetrahydrobenzo[c]chromen-1-ol  
12 Some trade or other names: HU-210;  
13 (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-  
14 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-  
15 tetrahydrobenzo[c]chromen-1-ol, its isomers,  
16 salts, and salts of isomers; Some trade or other  
17 names: HU-210, Dexanabinol;  
18 (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-  
19 6,6-dimethyl-3-(2-methyloctan-2-yl)-  
20 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol  
21 Some trade or other names: HU-211;  
22 (37) (Blank);  
23 (38) (Blank);  
24 (39) (Blank);  
25 (40) (Blank);  
26 (41) (Blank);

1           (42) Any compound structurally derived from  
2           3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane  
3           by substitution at the nitrogen atom of the indole ring by  
4           alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
5           cycloalkylethyl, aryl halide, alkyl aryl halide,  
6           1-(N-methyl-2-piperidinyl)methyl, or  
7           2-(4-morpholinyl)ethyl whether or not further substituted  
8           in the indole ring to any extent, whether or not  
9           substituted in the naphthyl ring to any extent. Examples of  
10          this structural class include, but are not limited to,  
11          JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;

12          (43) Any compound structurally derived from  
13          3-(1-naphthoyl)pyrrole by substitution at the nitrogen  
14          atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,  
15          cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
16          halide, 1-(N-methyl-2-piperidinyl)methyl, or  
17          2-(4-morpholinyl)ethyl, whether or not further substituted  
18          in the pyrrole ring to any extent, whether or not  
19          substituted in the naphthyl ring to any extent. Examples of  
20          this structural class include, but are not limited to,  
21          JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;

22          (44) Any compound structurally derived from  
23          1-(1-naphthylmethyl)indene by substitution at the  
24          3-position of the indene ring by alkyl, haloalkyl, alkenyl,  
25          cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
26          halide, 1-(N-methyl-2-piperidinyl)methyl, or

1 2-(4-morpholinyl)ethyl whether or not further substituted  
2 in the indene ring to any extent, whether or not  
3 substituted in the naphthyl ring to any extent. Examples of  
4 this structural class include, but are not limited to,  
5 JWH-176;

6 (45) Any compound structurally derived from  
7 3-phenylacetylindole by substitution at the nitrogen atom  
8 of the indole ring with alkyl, haloalkyl, alkenyl,  
9 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
10 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
11 2-(4-morpholinyl)ethyl, whether or not further substituted  
12 in the indole ring to any extent, whether or not  
13 substituted in the phenyl ring to any extent. Examples of  
14 this structural class include, but are not limited to,  
15 JWH-167, JWH-250, JWH-251, and RCS-8;

16 (46) Any compound structurally derived from  
17 2-(3-hydroxycyclohexyl)phenol by substitution at the  
18 5-position of the phenolic ring by alkyl, haloalkyl,  
19 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,  
20 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or  
21 2-(4-morpholinyl)ethyl, whether or not substituted in the  
22 cyclohexyl ring to any extent. Examples of this structural  
23 class include, but are not limited to, CP 47, 497 and its  
24 C8 homologue (cannabicyclohexanol);

25 (46.1) Any compound structurally derived from  
26 3-(benzoyl) indole with substitution at the nitrogen atom

1 of the indole ring by an alkyl, haloalkyl, alkenyl,  
2 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
3 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
4 2-(4-morpholinyl)ethyl group whether or not further  
5 substituted in the indole ring to any extent and whether or  
6 not substituted in the phenyl ring to any extent. Examples  
7 of this structural class include, but are not limited to,  
8 AM-630, AM-2233, AM-694, Pravadoline (WIN 48,098), and  
9 RCS-4;

10 (47) (Blank);

11 (48) (Blank);

12 (49) (Blank);

13 (50) (Blank);

14 (51) (Blank);

15 (52) (Blank);

16 (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine\_

17 Some trade or other names: 2C-T-7;

18 (53.1) 4-ethyl-2,5-dimethoxyphenethylamine\_ Some trade  
19 or other names: 2C-E;

20 (53.2) 2,5-dimethoxy-4-methylphenethylamine\_ Some  
21 trade or other names: 2C-D;

22 (53.3) 4-chloro-2,5-dimethoxyphenethylamine\_ Some  
23 trade or other names: 2C-C;

24 (53.4) 4-iodo-2,5-dimethoxyphenethylamine\_ Some trade  
25 or other names: 2C-I;

26 (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine\_ Some

1 trade or other names: 2C-T-2;

2 (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine\_

3 Some trade or other names: 2C-T-4;

4 (53.7) 2,5-dimethoxyphenethylamine\_ Some trade or

5 other names: 2C-H;

6 (53.8) 2,5-dimethoxy-4-nitrophenethylamine\_ Some trade

7 or other names: 2C-N;

8 (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine\_ Some

9 trade or other names: 2C-P;

10 (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine\_ Some

11 trade or other names: 2C-G;

12 (53.11) The N-(2-methoxybenzyl) derivative of any 2C

13 phenethylamine referred to in subparagraphs (20.1), (53),

14 (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),

15 (53.8), (53.9), and (53.10) including, but not limited to,

16 25I-NBOMe and 25C-NBOMe;

17 (54) 5-Methoxy-N,N-diisopropyltryptamine;

18 (55) (Blank);

19 (56) (Blank);

20 (57) (Blank);

21 (58) (Blank);

22 (59) 3-cyclopropoylindole with substitution at the

23 nitrogen atom of the indole ring by alkyl, haloalkyl,

24 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,

25 alkyl aryl halide, 1-(N-methyl-2-piperidiny)methyl, or

26 2-(4-morpholinyl)ethyl, whether or not further substituted

1 on the indole ring to any extent, whether or not  
2 substituted on the cyclopropyl ring to any extent:  
3 including, but not limited to, XLR11, UR144, FUB-144;

4 (60) 3-adamantoylindole with substitution at the  
5 nitrogen atom of the indole ring by alkyl, haloalkyl,  
6 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,  
7 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or  
8 2-(4-morpholinyl)ethyl, whether or not further substituted  
9 on the indole ring to any extent, whether or not  
10 substituted on the adamantyl ring to any extent: including,  
11 but not limited to, AB-001;

12 (61) N-(adamantyl)-indole-3-carboxamide with  
13 substitution at the nitrogen atom of the indole ring by  
14 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
15 cycloalkylethyl, aryl halide, alkyl aryl halide,  
16 1-(N-methyl-2-piperidinyl)methyl, or  
17 2-(4-morpholinyl)ethyl, whether or not further substituted  
18 on the indole ring to any extent, whether or not  
19 substituted on the adamantyl ring to any extent: including,  
20 but not limited to, APICA/2NE-1, STS-135;

21 (62) N-(adamantyl)-indazole-3-carboxamide with  
22 substitution at a nitrogen atom of the indazole ring by  
23 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
24 cycloalkylethyl, aryl halide, alkyl aryl halide,  
25 1-(N-methyl-2-piperidinyl)methyl, or  
26 2-(4-morpholinyl)ethyl, whether or not further substituted

1 on the indazole ring to any extent, whether or not  
2 substituted on the adamantyl ring to any extent: including,  
3 but not limited to, AKB48, 5F-AKB48;

4 (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester  
5 with substitution at the nitrogen atom of the indole ring  
6 by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
7 cycloalkylethyl, aryl halide, alkyl aryl halide,  
8 1-(N-methyl-2-piperidinyl)methyl, or  
9 2-(4-morpholinyl)ethyl, whether or not further substituted  
10 on the indole ring to any extent, whether or not  
11 substituted on the quinoline ring to any extent: including,  
12 but not limited to, PB22, 5F-PB22, FUB-PB-22;

13 (64) 3-(1-naphthoyl)indazole with substitution at the  
14 nitrogen atom of the indazole ring by alkyl, haloalkyl,  
15 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,  
16 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or  
17 2-(4-morpholinyl)ethyl, whether or not further substituted  
18 on the indazole ring to any extent, whether or not  
19 substituted on the naphthyl ring to any extent: including,  
20 but not limited to, THJ-018, THJ-2201;

21 (65) 2-(1-naphthoyl)benzimidazole with substitution at  
22 the nitrogen atom of the benzimidazole ring by alkyl,  
23 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
24 aryl halide, alkyl aryl halide,  
25 1-(N-methyl-2-piperidinyl)methyl, or  
26 2-(4-morpholinyl)ethyl, whether or not further substituted

1 on the benzimidazole ring to any extent, whether or not  
2 substituted on the naphthyl ring to any extent: including,  
3 but not limited to, FUBIMINA;

4 (66) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-  
5 3-carboxamide with substitution on the nitrogen atom of the  
6 indazole ring by alkyl, haloalkyl, alkenyl,  
7 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
8 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
9 2-(4-morpholinyl)ethyl, whether or not further substituted  
10 on the indazole ring to any extent: including, but not  
11 limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;

12 (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-  
13 indazole-3-carboxamide with substitution on the nitrogen  
14 atom of the indazole ring by alkyl, haloalkyl, alkenyl,  
15 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
16 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
17 2-(4-morpholinyl)ethyl, whether or not further substituted  
18 on the indazole ring to any extent: including, but not  
19 limited to, ADB-PINACA, ADB-FUBINACA;

20 (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-  
21 indole-3-carboxamide with substitution on the nitrogen  
22 atom of the indole ring by alkyl, haloalkyl, alkenyl,  
23 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
24 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
25 2-(4-morpholinyl)ethyl, whether or not further substituted  
26 on the indole ring to any extent: including, but not

1 limited to, ADBICA, 5F-ADBICA;

2 (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-  
3 3-carboxamide with substitution on the nitrogen atom of the  
4 indole ring by alkyl, haloalkyl, alkenyl,  
5 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
6 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
7 2-(4-morpholinyl)ethyl, whether or not further substituted  
8 on the indole ring to any extent: including, but not  
9 limited to, ABICA, 5F-ABICA;

10 (70) Methyl 2-(1H-indazole-3-carboxamido)-3-  
11 methylbutanoate with substitution on the nitrogen atom of  
12 the indazole ring by alkyl, haloalkyl, alkenyl,  
13 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
14 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
15 2-(4-morpholinyl)ethyl, whether or not further substituted  
16 on the indazole ring to any extent: including, but not  
17 limited to, AMB, 5F-AMB;

18 (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3-  
19 dimethylbutanoate with substitution on the nitrogen atom  
20 of the indazole ring by alkyl, haloalkyl, alkenyl,  
21 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
22 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
23 2-(4-morpholinyl)ethyl, whether or not further substituted  
24 on the indazole ring to any extent: including, but not  
25 limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;

26 (72) Methyl 2-(1H-indole-3-carboxamido)-3-

1 methylbutanoate with substitution on the nitrogen atom of  
2 the indole ring by alkyl, haloalkyl, alkenyl,  
3 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
4 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
5 2-(4-morpholinyl)ethyl, whether or not further substituted  
6 on the indazole ring to any extent: including, but not  
7 limited to, MMB018, MMB2201, and AMB-CHMICA;

8 (73) Methyl 2-(1H-indole-3-carboxamido)-3,3-  
9 dimethylbutanoate with substitution on the nitrogen atom  
10 of the indole ring by alkyl, haloalkyl, alkenyl,  
11 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
12 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
13 2-(4-morpholinyl)ethyl, whether or not further substituted  
14 on the indazole ring to any extent: including, but not  
15 limited to, MDMB-CHMICA;

16 (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-  
17 indazole-3-carboxamide with substitution on the nitrogen  
18 atom of the indazole ring by alkyl, haloalkyl, alkenyl,  
19 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
20 halide, 1-(N-methyl-2-piperidinyl)methyl, or  
21 2-(4-morpholinyl)ethyl, whether or not further substituted  
22 on the indazole ring to any extent: including, but not  
23 limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;

24 (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole-  
25 3-carboxamide with substitution on the nitrogen atom of the  
26 indole ring by alkyl, haloalkyl, alkenyl,

1           cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
2           halide,           1-(N-methyl-2-piperidinyl)methyl,           or  
3           2-(4-morpholinyl)ethyl, whether or not further substituted  
4           on the indazole ring to any extent: including, but not  
5           limited to, APP-PICA and 5-fluoro-APP-PICA;

6           (76)    4-Acetoxy-N,N-dimethyltryptamine:   trade   name  
7           4-AcO-DMT;

8           (77)    5-Methoxy-N-methyl-N-isopropyltryptamine:   trade  
9           name 5-MeO-MIPT;

10           (78) 4-hydroxy Diethyltryptamine (4-HO-DET);

11           (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);

12           (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);

13           (81)            4-hydroxy-N-methyl-N-isopropyltryptamine  
14           (4-HO-MiPT);

15           (82) Fluorophenylpiperazine;

16           (83) Methoxetamine;

17           (84)    1-(Ethylamino)-2-phenylpropan-2-one           (iso-  
18           ethcathinone).

19           (e) Unless specifically excepted or unless listed in  
20           another schedule, any material, compound, mixture, or  
21           preparation which contains any quantity of the following  
22           substances having a depressant effect on the central nervous  
23           system, including its salts, isomers, and salts of isomers  
24           whenever the existence of such salts, isomers, and salts of  
25           isomers is possible within the specific chemical designation:

26           (1) mecloqualone;

1 (2) methaqualone; and

2 (3) gamma hydroxybutyric acid.

3 (f) Unless specifically excepted or unless listed in  
4 another schedule, any material, compound, mixture, or  
5 preparation which contains any quantity of the following  
6 substances having a stimulant effect on the central nervous  
7 system, including its salts, isomers, and salts of isomers:

8 (1) Fenethylline;

9 (2) N-ethylamphetamine;

10 (3) Aminorex (some other names:

11 2-amino-5-phenyl-2-oxazoline; aminoxaphen;

12 4-5-dihydro-5-phenyl-2-oxazolamine) and its

13 salts, optical isomers, and salts of optical isomers;

14 (4) Methcathinone (some other names:

15 2-methylamino-1-phenylpropan-1-one;

16 Ephedrone; 2-(methylamino)-propiofenone;

17 alpha-(methylamino)propiofenone; N-methylcathinone;

18 methcathinone; Monomethylpropion; UR 1431) and its

19 salts, optical isomers, and salts of optical isomers;

20 (5) Cathinone (some trade or other names:

21 2-aminopropiofenone; alpha-aminopropiofenone;

22 2-amino-1-phenyl-propanone; norephedrone);

23 (6) N,N-dimethylamphetamine (also known as:

24 N,N-alpha-trimethyl-benzeneethanamine;

25 N,N-alpha-trimethylphenethylamine);

26 (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-

- 1 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
- 2 (8) 3,4-Methylenedioxypropylamphetamine (MDPV);
- 3 (9) Halogenated amphetamines and
- 4 methamphetamines - any compound derived from either
- 5 amphetamine or methamphetamine through the substitution
- 6 of a halogen on the phenyl ring, including, but not
- 7 limited to, 2-fluoroamphetamine, 3-
- 8 fluoroamphetamine and 4-fluoroamphetamine;
- 9 (10) Aminopropylbenzofuran (APB):
- 10 including 4-(2-Aminopropyl) benzofuran, 5-
- 11 (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
- 12 benzofuran, and 7-(2-Aminopropyl) benzofuran;
- 13 (11) Aminopropyldihydrobenzofuran (APDB):
- 14 including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
- 15 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
- 16 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
- 17 and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran;
- 18 (12) Methylaminopropylbenzofuran
- 19 (MAPB): including 4-(2-methylaminopropyl)
- 20 benzofuran, 5-(2-methylaminopropyl)benzofuran,
- 21 6-(2-methylaminopropyl)benzofuran
- 22 and 7-(2-methylaminopropyl)benzofuran.
- 23 (g) Temporary listing of substances subject to emergency
- 24 scheduling. Any material, compound, mixture, or preparation
- 25 that contains any quantity of the following substances:
- 26 (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide

1 (benzylfentanyl), its optical isomers, isomers, salts, and  
2 salts of isomers;

3 (2) N-[1(2-thienyl) methyl-4-piperidyl]-N-  
4 phenylpropanamide (thenylfentanyl), its optical isomers,  
5 salts, and salts of isomers.

6 (h) Synthetic cathinones. Unless specifically excepted,  
7 any chemical compound which is not approved by the United  
8 States Food and Drug Administration or, if approved, is not  
9 dispensed or possessed in accordance with State or federal law,  
10 not including bupropion, structurally derived from  
11 2-aminopropan-1-one by substitution at the 1-position with  
12 either phenyl, naphthyl, or thiophene ring systems, whether or  
13 not the compound is further modified in one or more of the  
14 following ways:

15 (1) by substitution in the ring system to any extent  
16 with alkyl, alkylendioxy, alkoxy, haloalkyl, hydroxyl, or  
17 halide substituents, whether or not further substituted in  
18 the ring system by one or more other univalent  
19 substituents. Examples of this class include, but are not  
20 limited to, 3,4-Methylenedioxycathinone (bk-MDA);

21 (2) by substitution at the 3-position with an acyclic  
22 alkyl substituent. Examples of this class include, but are  
23 not limited to, 2-methylamino-1-phenylbutan-1-one  
24 (buphedrone); or

25 (3) by substitution at the 2-amino nitrogen atom with  
26 alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by

1 inclusion of the 2-amino nitrogen atom in a cyclic  
2 structure. Examples of this class include, but are not  
3 limited to, Dimethylcathinone, Ethcathinone, and  
4 a-Pyrrolidinopropiophenone (a-PPP); ~~or~~

5 Any other synthetic cathinone which is not approved by the  
6 United States Food and Drug Administration or, if approved, is  
7 not dispensed or possessed in accordance with State or federal  
8 law.

9 (i) Synthetic cannabinoids or piperazines. Any synthetic  
10 cannabinoid or piperazine which is not approved by the United  
11 States Food and Drug Administration or, if approved, which is  
12 not dispensed or possessed in accordance with State and federal  
13 law.

14 (Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17;  
15 100-368, eff. 1-1-18; revised 10-5-17.)